Metformin impairs systemic bile acid homeostasis through regulating SIRT1 protein levels

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1864, Issue 1, 2017, Pages 101-112

  Chen, Qi ^a,b   Yang, Xiaoying ^a   Zhang, Huabing ^a   Kong, Xingxing ^a   Yao, Lu ^a   Cui, Xiaona ^a   Zou, Yongkang ^a   Fang, Fude ^a   Yang, Jichun ^c   Chang, Yongsheng ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b Hangzhou Center for Disease Control and Prevention   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Bile acid metabolism; Deacetylate; Foxa2; Metformin; SIRT1

Indexed keywords

BETA TUBULIN; BILE ACID; BILE SALT EXPORT PUMP; CHOLESTANETRIOL 26 MONOOXYGENASE; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; CYTOCHROME P450 3A11; FARNESOID X RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3BETA; HISTONE ACETYLTRANSFERASE; METFORMIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; SIRTUIN 1; SODIUM BILE ACID COTRANSPORTER; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; FOXA2 PROTEIN, MOUSE; SIRT1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE ACID BLOOD LEVEL; BILE ACID METABOLISM; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DEACETYLATION; HOMEOSTASIS; LIVER; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN BINDING; TRIACYLGLYCEROL BLOOD LEVEL; WILD TYPE; ACETYLATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEP-G2 CELL LINE; HUMAN; INTRAHEPATIC CHOLESTASIS; MALE; METABOLISM; MUTATION; PATHOLOGY; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ACETYLATION; ANIMALS; BILE ACIDS AND SALTS; CHOLESTASIS, INTRAHEPATIC; GENE EXPRESSION REGULATION; HEP G2 CELLS; HEPATOCYTE NUCLEAR FACTOR 3-BETA; HEPATOCYTES; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; MALE; METFORMIN; MICE; MICE, TRANSGENIC; MUTATION; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; SIRTUIN 1;

EID: 84994527363     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2016.10.020     Document Type: Article

References (43)

1. [1] Kirpichnikov, D., McFarlane, S.I., Sowers, J.R., Metformin: an update. Ann. Intern. Med. 137 (2002), 25–33.
2. [2] Hundal, R.S., Krssak, M., Dufour, S., Laurent, D., Lebon, V., Chandramouli, V., Inzucchi, S.E., Schumann, W.C., Petersen, K.F., Landau, B.R., Shulman, G.I., Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49 (2000), 2063–2069.
3. [3] Bailey, C.J., Turner, R.C., Metformin. N. Engl. J. Med. 334 (1996), 574–579.
4. [4] Lien, F., Berthier, A., Bouchaert, E., Gheeraert, C., Alexandre, J., Porez, G., Prawitt, J., Dehondt, H., Ploton, M., Colin, S., Lucas, A., Patrice, A., Pattou, F., Diemer, H., Van Dorsselaer, A., Rachez, C., Kamilic, J., Groen, A.K., Staels, B., Lefebvre, P., Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk. J. Clin. Invest. 124 (2014), 1037–1051.
5. [5] Desilets, D.J., Shorr, A.F., Moran, K.A., Holtzmuller, K.C., Cholestatic jaundice associated with the use of metformin. Am. J. Gastroenterol. 96 (2001), 2257–2258.
6. [6] Nammour, F.E., Fayad, N.F., Peikin, S.R., Metformin-induced cholestatic hepatitis. Endocr. Pract. 9 (2003), 307–309.
7. [7] Kutoh, E., Possible metformin-induced hepatotoxicity. Am. J. Geriatr. Pharmacother. 3 (2005), 270–273.
8. [8] Biyyani, R.S., Battula, S., Erhardt, C.A., Korkor, K., Metformin-induced cholangiohepatitis. BMJ Case Rep., 2009, 2009.
9. [9] Chiang, J.Y., Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J. Hepatol. 40 (2004), 539–551.
10. [10] de Aguiar Vallim, T.Q., Tarling, E.J., Edwards, P.A., Pleiotropic roles of bile acids in metabolism. Cell Metab. 17 (2013), 657–669.
11. [11] Sinal, C.J., Tohkin, M., Miyata, M., Ward, J.M., Lambert, G., Gonzalez, F.J., Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102 (2000), 731–744.
12. [12] Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C.L., McDonald, J.G., Luo, G., Jones, S.A., Goodwin, B., Richardson, J.A., Gerard, R.D., Repa, J.J., Mangelsdorf, D.J., Kliewer, S.A., Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2 (2005), 217–225.
13. [13] Kaestner, K.H., The hepatocyte nuclear factor 3 (HNF3 or FOXA) family in metabolism. Trends Endocrinol. Metab. 11 (2000), 281–285.
14. [14] Zhang, L., Rubins, N.E., Ahima, R.S., Greenbaum, L.E., Kaestner, K.H., Foxa2 integrates the transcriptional response of the hepatocyte to fasting. Cell Metab. 2 (2005), 141–148.
15. [15] Friedman, J.R., Kaestner, K.H., The Foxa family of transcription factors in development and metabolism. Cell. Mol. Life Sci. 63 (2006), 2317–2328.
16. [16] Wolfrum, C., Asilmaz, E., Luca, E., Friedman, J.M., Stoffel, M., Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature 432 (2004), 1027–1032.
17. [17] Wolfrum, C., Stoffel, M., Coactivation of Foxa2 through Pgc-1beta promotes liver fatty acid oxidation and triglyceride/VLDL secretion. Cell Metab. 3 (2006), 99–110.
18. [18] Bochkis, I.M., Rubins, N.E., White, P., Furth, E.E., Friedman, J.R., Kaestner, K.H., Hepatocyte-specific ablation of Foxa2 alters bile acid homeostasis and results in endoplasmic reticulum stress. Nat. Med. 14 (2008), 828–836.
19. [19] Rausa, F.M., Tan, Y., Zhou, H., Yoo, K.W., Stolz, D.B., Watkins, S.C., Franks, R.R., Unterman, T.G., Costa, R.H., Elevated levels of hepatocyte nuclear factor 3beta in mouse hepatocytes influence expression of genes involved in bile acid and glucose homeostasis. Mol. Cell. Biol. 20 (2000), 8264–8282.
20. [20] Imai, S., Armstrong, C.M., Kaeberlein, M., Guarente, L., Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403 (2000), 795–800.
21. [21] Liang, F., Kume, S., Koya, D., SIRT1 and insulin resistance. Nat. Rev. Endocrinol. 5 (2009), 367–373.
22. [22] Purushotham, A., Schug, T.T., Xu, Q., Surapureddi, S., Guo, X., Li, X., Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 9 (2009), 327–338.
23. [23] Li, X., Zhang, S., Blander, G., Tse, J.G., Krieger, M., Guarente, L., SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol. Cell 28 (2007), 91–106.
24. [24] Picard, F., Kurtev, M., Chung, N., Topark-Ngarm, A., Senawong, T., Machado De Oliveira, R., Leid, M., McBurney, M.W., Guarente, L., Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429 (2004), 771–776.
25. [25] Brunet, A., Sweeney, L.B., Sturgill, J.F., Chua, K.F., Greer, P.L., Lin, Y., Tran, H., Ross, S.E., Mostoslavsky, R., Cohen, H.Y., Hu, L.S., Cheng, H.L., Jedrychowski, M.P., Gygi, S.P., Sinclair, D.A., Alt, F.W., Greenberg, M.E., Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303 (2004), 2011–2015.
26. [26] Rodgers, J.T., Lerin, C., Haas, W., Gygi, S.P., Spiegelman, B.M., Puigserver, P., Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434 (2005), 113–118.
27. [27] Rodgers, J.T., Puigserver, P., Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 12861–12866.
28. [28] Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., Musi, N., Hirshman, M.F., Goodyear, L.J., Moller, D.E., Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108 (2001), 1167–1174.
29. [29] Shaw, R.J., Lamia, K.A., Vasquez, D., Koo, S.H., Bardeesy, N., Depinho, R.A., Montminy, M., Cantley, L.C., The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310 (2005), 1642–1646.
30. [30] Foretz, M., Hebrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., Viollet, B., Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest. 120 (2010), 2355–2369.
31. [31] Silva, J.P., Wahlestedt, C., Role of Sirtuin 1 in metabolic regulation. Drug Discov. Today 15 (2010), 781–791.
32. [32] Kerr, T.A., Saeki, S., Schneider, M., Schaefer, K., Berdy, S., Redder, T., Shan, B., Russell, D.W., Schwarz, M., Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis. Dev. Cell 2 (2002), 713–720.
33. [33] Erion, D.M., Yonemitsu, S., Nie, Y., Nagai, Y., Gillum, M.P., Hsiao, J.J., Iwasaki, T., Stark, R., Weismann, D., Yu, X.X., Murray, S.F., Bhanot, S., Monia, B.P., Horvath, T.L., Gao, Q., Samuel, V.T., Shulman, G.I., SirT1 knockdown in liver decreases basal hepatic glucose production and increases hepatic insulin responsiveness in diabetic rats. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 11288–11293.
34. [34] Geerling, J.J., Boon, M.R., van der Zon, G.C., van den Berg, S.A., van den Hoek, A.M., Lombes, M., Princen, H.M., Havekes, L.M., Rensen, P.C., Guigas, B., Metformin lowers plasma triglycerides by promoting VLDL-triglyceride clearance by brown adipose tissue in mice. Diabetes 63 (2014), 880–891.
35. [35] Liu, F., Wang, C., Zhang, L., Xu, Y., Jang, L., Gu, Y., Cao, X., Zhao, X., Ye, J., Li, Q., Metformin prevents hepatic steatosis by regulating the expression of adipose differentiation-related protein. Int. J. Mol. Med. 33 (2014), 51–58.
36. [36] Cheng, H.L., Mostoslavsky, R., Saito, S., Manis, J.P., Gu, Y., Patel, P., Bronson, R., Appella, E., Alt, F.W., Chua, K.F., Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 10794–10799.
37. [37] Korzus, E., Torchia, J., Rose, D.W., Xu, L., Kurokawa, R., McInerney, E.M., Mullen, T.M., Glass, C.K., Rosenfeld, M.G., Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science 279 (1998), 703–707.
38. [38] Kohler, S., Cirillo, L.A., Stable chromatin binding prevents FoxA acetylation, preserving FoxA chromatin remodeling. J. Biol. Chem. 285 (2010), 464–472.
39. [39] Wang, R.H., Xu, X., Kim, H.S., Xiao, Z., Deng, C.X., SIRT1 deacetylates FOXA2 and is critical for Pdx1 transcription and beta-cell formation. Int. J. Biol. Sci. 9 (2013), 934–946.
40. [40] von Meyenn, F., Porstmann, T., Gasser, E., Selevsek, N., Schmidt, A., Aebersold, R., Stoffel, M., Glucagon-induced acetylation of Foxa2 regulates hepatic lipid metabolism. Cell Metab. 17 (2013), 436–447.
41. [41] van Gent, R., Di Sanza, C., van den Broek, N.J., Fleskens, V., Veenstra, A., Stout, G.J., Brenkman, A.B., SIRT1 mediates FOXA2 breakdown by deacetylation in a nutrient-dependent manner. PLoS One, 9, 2014, e98438.
42. [42] Purushotham, A., Xu, Q., Lu, J., Foley, J.F., Yan, X., Kim, D.H., Kemper, J.K., Li, X., Hepatic deletion of SIRT1 decreases hepatocyte nuclear factor 1alpha/farnesoid X receptor signaling and induces formation of cholesterol gallstones in mice. Mol. Cell. Biol. 32 (2012), 1226–1236.
43. [43] Kemper, J.K., Xiao, Z., Ponugoti, B., Miao, J., Fang, S., Kanamaluru, D., Tsang, S., Wu, S.Y., Chiang, C.M., Veenstra, T.D., FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. Cell Metab. 10 (2009), 392–404.